Company Overview - FormFactor has a global presence with approximately 2,150 employees and manufactures over 115 million MEMS probes annually[7] - The company's trailing twelve months (TTM) revenue as of October 30, 2024, was $742 million[7] - FormFactor is recognized by industry leaders such as Intel, Samsung, Micron, SK hynix, and TSMC[7] Financial Performance - In 2023, FormFactor's revenue was $663 million[20] - The company's non-GAAP EPS in 2023 was $0.73[20] - The free cash flow for 2023 was $11 million[20] - The non-GAAP gross margin in 2023 was 40.7%[20] - The target model revenue is $850 million, with a target non-GAAP EPS of $2.00[87] - The target free cash flow is $160 million[87] Market and Growth - The advanced probe card market is estimated to be $2.0 billion, while the engineering systems market is $0.5 billion[47] - The advanced probe card market is expected to grow at an annual rate of 8%[52] - The engineering systems market is expected to grow at an annual rate of 3%[52] - FormFactor estimates its growth in the advanced probe card market to be 10%+ CAGR[79]

2025 WESTERN BANK FORUM MARCH 10 - 11, 2025 MARINA DEL REY, CALIFORNIA INVESTOR PRESENTATION SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the current beliefs and expectations of Sierra Bancorp's management and are: Actual results may differ from those set forth in the forward-looking statements. Factors that could cause Sierra Bancorp's actual results to differ materially ...

Bicycle Therapeutics Investor Presentation • May 2025 Forward-looking statements Bicycle® molecules are short peptides chemically constrained with a central scaffold that can induce diverse structures Scaffold Chemical modification with scaffold Short linear peptide + Bicycle® molecule This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "antici ...

UL SOLUTIONS INC. Disclaimer This presentation and related discussion are being presented by UL Solutions ("UL Solutions," the "Company," "we," "us" and "our") solely for informational purposes. This presentation and accompanying statements contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation and related discussion may be forward-looking statements. These includ ...

Company Overview - Gyre Therapeutics is a pioneering fibrosis treatment company with a track record of success, including being the first to receive IPF treatment approval (pirfenidone) in China in 2011[7] - The company has maintained a leading IPF market share in China for 10 consecutive years, with approximately 50% overall market share and over 90% share in pirfenidone in 2024[7] - Gyre Therapeutics has approximately 600 dedicated global employees, including around 400 in commercial teams across China and the U S and about 70 focused on R&D[7] - In 2024, Gyre Therapeutics achieved revenue of $105 8 million[8] Hydronidone (F351) Development - Hydronidone (F351) is Gyre's lead asset with the potential to be a first-in-class therapy for CHB-related liver fibrosis, addressing a significant unmet medical need in China, and is expected to initiate a Phase 2 trial in the U S for the treatment of MASH-associated liver fibrosis[11] - In a Phase 2 trial, Hydronidone demonstrated significant fibrosis improvement, with 54 8% of patients in the combined Hydronidone groups showing ≥1 stage fibrosis improvement at Week 52, compared to 25 6% in the placebo group[17] - The U S MASH fibrosis market is estimated to be 7 2 times larger than the CHB fibrosis market[24] Strategic Acquisitions and Future Outlook - Gyre acquired Nintedanib and Avatrombopag in 2024 to strengthen its pirfenidone franchise and prepare for the potential future launch of Hydronidone[45] - The company forecasts 2025 sales of $118 million to $128 million[45] - Gyre expects to submit a New Drug Application (NDA) for Hydronidone in Q2 2025, with NMPA approval anticipated in 2026[53]

Financial Performance - The company's total assets reached $1.6 billion as of June 30, 2024 [12] - Net income for the second quarter of 2024 was $6.786 million, a 1.9% increase compared to $6.660 million in the second quarter of 2023 [80] - Net interest income for the second quarter of 2024 increased by 6.8% to $18.405 million from $17.239 million in the second quarter of 2023 [80] - The net interest margin for 2023 was 4.71%, driven by higher rates and strategic investments [30] - In 2023, net income increased by 12.6% to $29.776 million [82] Deposits and Loans - As of June 30, 2024, non-interest-bearing deposits accounted for 51% of total deposits [45] - The average interest-bearing deposit rate was 0.84% for the three months ended June 30, 2024 [44] - Total loans reached $997 million as of June 30, 2024 [58] - Agricultural lending balances represented 12.5% of total loans as of June 30, 2024 [71] Investments and Borrowings - The investment portfolio totaled $445 thousand [41] - Securities totaling $115 million were sold in 1Q24, resulting in a $19.8 million loss [41] - Outstanding BTFP borrowings amounted to $105 million with a rate of 4.85% [55]

Nevada County INVESTOR PRESENTATION UPDATED THROUGH SEPTEMBER 30, 2024 1 Forward Looking Statements Disclaimer The statements contained herein that are not historical facts are forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. Such statements involve inherent risks and uncertainties, many of which are difficult to predict and are generally beyond our control. There can be no assurance that future devel ...

Financial Performance - Net income decreased by 389% from $29776 thousand in 2023 to $28619 thousand in 2024[82] - Net interest income increased by 558% from $69794 thousand in 2023 to $73691 thousand in 2024[82] - The net interest margin increased by 170% from 471% in 2023 to 479% in 2024[82] - Return on average assets(ROAA) decreased by 745% from 188% in 2023 to 174% in 2024[82] - Return on average equity(ROAE) decreased by 265% from 234% in 2023 to 172% in 2024[82] Balance Sheet - Total assets increased by 080% from $1610416 thousand in 2023 to $1623326 thousand in 2024[82] - Total deposits increased by 281% from $1333655 thousand in 2023 to $1371101 thousand in 2024[82] - Net loans increased by 598% from $948604 thousand in 2023 to $1005375 thousand in 2024[82] Loan Portfolio - Government guaranteed loans represented approximately 7% of total loans as of December 31 2024[67] - Agricultural lending balances represented 12% of total loans as of December 31 2024[71]

Renewables Portfolio and Growth - AES has a global operating and development portfolio of 66 GW[7] - The company's pipeline includes 12.7 GW of projects[7] - AES' backlog consists of 34.9 GW, with 46% under construction[7,8] - The company expects to add a total of 3.6 GW of new projects in FY 2024[8] Data Center Demand and AES' Position - US data center demand is projected to grow by 35 GW by 2030, driven by GenAI[11] - Over 40% of AES' US backlog is with large technology companies[16] - AES has signed PPAs totaling 5.91 GW with Amazon, Microsoft, Google, and other companies[15] Financial Performance and Targets - AES reaffirmed its 2024 Adjusted EPS guidance of $1.87-$1.97 per share[21] - The company reaffirmed its 2024 Adjusted EBITDA with Tax Attributes guidance of $3.55 billion - $3.95 billion[21] - AES has achieved $2.2 billion in asset sale proceeds for 2023-2024, with a remaining target of $1.3 billion for 2024-2027, totaling $3.5 billion[23,24] - The sale of AES Brasil is expected to generate ~$640 million in proceeds[25]

Company Overview and Strategy - Finward Bancorp has grown from $776 million to $2.1 billion in assets over the last 10 years, representing a 10.3% CAGR[7] - The company aims to build capital and increase returns while positioning for different economic and interest rate outcomes[7] - The company is evaluating opportunities to optimize the balance sheet and improve earnings quality[7] Financial Performance - Total assets were $2.075 billion as of September YTD 2024[11] - Total loans were $1.508 billion as of September YTD 2024[11] - Total deposits were $1.748 billion as of September YTD 2024[11] - Total equity was $160 million as of September YTD 2024[11] - The tax-adjusted net interest margin was 2.67% for the three months ended September 30, 2024[22] Asset Quality and Loan Portfolio - Non-performing loans totaled $13.8 million, representing 0.92% of total loans as of September 30, 2024[48] - The bank originated $70.4 million in new commercial loans during the quarter ended September 30, 2024[39] - Total 1-4 family originations for the quarter ended September 30, 2024, totaled $20.1 million[39]